The 2025 ESC/EACTS guidelines for valvular heart disease bring significant updates that will influence the diagnosis, referral and treatment of patients with mitral and tricuspid regurgitation. In this round table discussion, three leading experts – Dr Victoria Delgado (University Hospital Germans Trias, Barcelona, ES), Prof Marco Metra (University and Civil Hospitals of Brescia, Brescia, IT), and Prof Philipp Lurz (Mainz University Medical Center, Mainz, DE) – review the latest evidence supporting MitraClip’s Class I upgrade, the implications on referrals and its impact on clinical practice. On the right side, in light of the indication upgrade, the discussion emphasises the importance of early diagnosis and treatment to positively influence prognosis in tricuspid patients.

Watch the full video, or key discussion points at the following video times: 

• 1:27 – Key trial messages behind MitraClip’s Class I upgrade
• 4:07 – Raising community awareness of tricuspid regurgitation
• 8:44 – Need for more trials versus sufficient evidence
• 12:44 – Community needs to better identify tricuspid patients
• 14:32 – Expanded Class IIa guidelines for broader eligibility for transcatheter tricuspid repair with TriClip
• 18:32 – Current practices and future directions in tricuspid therapies